FDA
The US Food and Drug Administration, the agency that regulates and approves drugs and medical devices.
As defined in Peter Thiel
Where it comes up · 14
- Casey Mulligan on Vaccines, the Pandemic, and the FDA7 claims
- Jacob Stegenga on Medical Nihilism6 claims
- Marcia Angell on Big Pharma4 claims
- Adam Cifu on Ending Medical Reversal3 claims
- Vincent Rajkumar on the High Price of Cancer Drugs3 claims
- Atul Gawande2 claims
- Tyler Cowen on the COVID-19 Pandemic2 claims
- Peter Thiel1 claim
and 6 more
Most important claims · 10 of 34Search all claims for “FDA” →
- Traditional small-scale Mexican dry-aging—putting meat out until it turns green while people shake off flies—is labor intensive and would not pass FDA inspection standards, whereas US dry-aged beef is produced more systematically inside large institutions and costs several times more than non-aged beef, so demand for it here is limited.Tyler Cowen on Food
- Flibanserin, a drug for low female libido, was initially rejected by the FDA for tiny benefits and notable harms (including poor reaction with alcohol) but approved after pressure from a patient advocacy group ('Even the Score') that turned out to be funded by the drug's maker; tellingly, the study of its harmful side effects had a majority of male subjects.Jacob Stegenga on Medical Nihilism
- The economists' argument that slow FDA approval kills people presupposes a pipeline of many lifesaving drugs being held up, but there is no such pipeline—in the last 50 years only a tiny handful of drugs (e.g. Gleevec, HIV drugs) have consistently extended lifespan—and the FDA already permits early use of experimental drugs for dying patients, so the higher bar likely saves more lives than it costs by keeping out harmful drugs.Jacob Stegenga on Medical Nihilism
- Rather than blocking access, the FDA can reasonably approve a needed drug on surrogate-endpoint evidence, but it should require that studies of real clinical endpoints be ongoing at the time of approval; the problem is these confirmatory studies often never get done, leaving us using therapies that might not work.Adam Cifu on Ending Medical Reversal
- FDA approval mainly requires two positive RCTs showing benefit over placebo or competitor, with thin safety data at that stage; the vast majority of harm evidence comes only after approval, and that post-approval evidence amounts to a collection of first-person anecdotes uploaded to databases, with carefully controlled randomized harm trials being rare.Jacob Stegenga on Medical Nihilism
- The FDA's evidential standard—two positive Phase 3 RCTs in which a drug is any amount better than placebo or a competitor—is far too low, because it specifies neither how much better the drug must be nor what kind of statistical inference is required, making it too easy to approve drugs with a negative benefit-harm profile.Jacob Stegenga on Medical Nihilism
- Regulators like the FDA can access large amounts of patient-level data that never reaches publication, but in practice they typically approve when two positive RCTs are found rather than using the full data to guide decisions.Jacob Stegenga on Medical Nihilism
- The high cost and delay of FDA approval, while disliked by industry for slowing drugs to market, simultaneously creates a barrier to entry that functions like a cartel protecting incumbent pharmaceutical companies from competition—and these subtle influences give the FDA incentives to keep industry somewhat happy, analogous to the symbiosis between banks and ratings agencies.Adam Cifu on Ending Medical Reversal
- Internal GlaxoSmithKline memos, leaked via a peer reviewer who faxed Nissen's manuscript to the company, revealed that GSK had already done its own meta-analysis of the unpublished data showing Rosiglitazone increased heart attacks and had shared it with the FDA, yet no regulatory decision changed—a case where the regulator had access to the full data or its meta-analysis and did not alter its stance.Jacob Stegenga on Medical Nihilism
- The federal government's wait-and-see refusal to legalize marijuana paradoxically makes the legal state-level business more dangerous and worse-regulated: banks won't serve it so it operates in cash (inviting robbery), and the FDA's expertise is barred from setting safety and driving rules, leaving tiny inexperienced state bureaucracies to write the rules everyone may eventually follow.Tom Wainwright on Narconomics